How RNA modifications affect blood vessel growth in lung cancer
3' RNA modification enzymes regulate tumor angiogenesis in non-small lung cancer
This study is looking at how certain changes in RNA in blood vessel cells affect the growth of tumors in people with non-small cell lung cancer, and it hopes to find new ways to help improve treatment for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10791492 on NIH RePORTER |
What this research studies
This research investigates the role of specific RNA modifications in tumor endothelial cells (TECs) and their impact on blood vessel growth in non-small cell lung cancer (NSCLC). The study focuses on how vascular endothelial growth factor (VEGF) influences the levels of microRNAs, particularly miR-1, which is known to suppress tumor growth. By analyzing TECs from NSCLC patients, the researchers aim to understand the mechanisms behind miR-1 downregulation and its effects on tumor angiogenesis. The findings could lead to new therapeutic strategies targeting these molecular pathways to improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer, particularly those with KRAS mutations or p53 abnormalities.
Not a fit: Patients with other types of lung cancer or those without the specific genetic mutations being studied may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to novel treatments that inhibit tumor blood vessel growth, potentially reducing tumor size and improving survival rates for lung cancer patients.
How similar studies have performed: Previous studies have shown promising results in targeting microRNAs for cancer treatment, indicating that this approach has potential for success.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Takyar, Seyedtaghi — Yale University
- Study coordinator: Takyar, Seyedtaghi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.